Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$73.24 USD

73.24
112,436

-0.23 (-0.31%)

Updated May 21, 2024 10:59 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 34% (164 out of 248)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.

    Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

    by Zacks Equity Research

    Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

      Will Buyouts Help Quest Diagnostics (DGX) Beat Q1 Earnings?

      by Zacks Equity Research

      Quest Diagnostics' (DGX) successful strategies to build esoteric testing business and boost profit margins raise optimism among investors on the stock.

        What's in Store for GNC Holdings (GNC) This Earnings Season?

        by Zacks Equity Research

        GNC Holdings (GNC) likely to witness year-over-year decline in revenues owing to weakness in the U.S. & Canada and Manufacturing/Wholesale segments in Q1.

          Henry Schein Ties Up With Internet Brands to Boost Dental Arm

          by Zacks Equity Research

          Henry Schein (HSIC) banks on part of its strategic plan, digital dentistry. In this regard, its latest joint venture with Internet Brands buoys optimism.

            Gargi Seth headshot

            Dental Implant & Prosthetic Boom Puts Spotlight on 3 Stocks

            by Gargi Seth

            The dental market has outperformed the broader market in last ten years on the back of demand from both teenagers and adults.

              Will Walgreens' (WBA) Q2 Earnings Gain From Overall Growth?

              by Zacks Equity Research

              Walgreens Boots' (WBA) increase in sales at the Retail Pharmacy International segment, on account of the company's strategic tie-ups, along with strength in other businesses buoy optimism.

                Is Henry Schein (HSIC) a Viable Stock for Value Investors?

                by Zacks Equity Research

                Henry Schein (HSIC) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.

                  Henry Schein (HSIC) Down 3.3% Since Earnings Report: Can It Rebound?

                  by Zacks Equity Research

                  Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Henry Schien to Distribute Grifols Product in United States

                    by Zacks Equity Research

                    We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.

                      Henry Schein (HSIC) Q4 Earnings in Line, 2018 View Upbeat

                      by Zacks Equity Research

                      Henry Schein's (HSIC) strong share gains in the North American and overseas markets along with solid revenues raise optimism.

                        Henry Schein (HSIC) Q4 Earnings in Line, Revenues Beat

                        by Zacks Equity Research

                        Henry Schein's (HSIC) four global segments gained solid market share during Q4 and delivered solid earnings growth.

                          Henry Schein (HSIC) Q4 Earnings to Show Growth in All Lines?

                          by Zacks Equity Research

                          Henry Schein (HSIC) likely to gain on strength across all business segments in Q4.

                            What's in Store for GNC Holdings (GNC) This Earnings Season?

                            by Zacks Equity Research

                            GNC Holdings (GNC) likely to see decline in year-over-year revenues owing to weakness in U.S. & Canada segment in Q4.

                              Will Covance Drug Development Drive LabCorp (LH) Q4 Earnings?

                              by Zacks Equity Research

                              LabCorp (LH) is expected to gain from LabCorp Diagnostics and Covance Drug Development segments in Q4.

                                Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

                                by Zacks Equity Research

                                Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                  Is AmerisourceBergen (ABC) Poised for a Beat in Q1 Earnings?

                                  by Zacks Equity Research

                                  AmerisourceBergen's (ABC) Q1 results are expected to gain on strength in pharmaceutical distribution segment.

                                    What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?

                                    by Zacks Equity Research

                                    Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.

                                      What to Expect From Quest Diagnostics (DGX) in Q4 Earnings

                                      by Zacks Equity Research

                                      Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.

                                        Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

                                        by Zacks Equity Research

                                        Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

                                          Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?

                                          by Zacks Equity Research

                                          IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.

                                            Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

                                            by Zacks Equity Research

                                            Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

                                              Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

                                              by Zacks Equity Research

                                              Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

                                                Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?

                                                by Zacks Equity Research

                                                Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.

                                                  Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

                                                  by Zacks Equity Research

                                                  Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.